Why the study?
Does full therapeutic intravenous heparin reduce the incidence of deep venous thrombosis compared to 1,000 units of heparin daily in patients with acute myocardial infarction?
Does full therapeutic intravenous heparin reduce the incidence of deep venous thrombosis compared to 1,000 units of heparin daily in patients with acute myocardial infarction?
Full therapeutic intravenous heparin does not significantly reduce the incidence of deep venous thrombosis compared to low-dose heparin (1,000 units daily) in patients with acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
Therapeutic IV heparin confers no DVT prevention advantage over low-dose in acute MI; challenges routine use of full anticoagulation for this purpose.
A prospective trial of the incidence of deep venous thrombosis as detected by the 125I-labelledfibrinogen tech- nique was performed in patients with acute myocardial infarction. One hundred and sixteen patients completed the trial and were randomly allocated full therapeutic heparin dosage intravenously (63 patients), while control patients received I,OOO units of heparin daily. The incidence of venous thromboses in the control group was not significantly different from the therapeutic group (I2.7% and 9 4%, respectively). The previously documented low incidence of clinicalfeatures of calf vein thrombosis was confirmed.
No takes yet. Share an insight, caveat, or question.
Habersberger et al. (1973) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: